Replies to post #327978 on Avid Bioservices Inc (CDMO)

[biopharm]

Swg, I can't make sense of that and a jury would only look at IF the new BODs were meeting fiduciary duties, which includes all IP assets.

As for $200 Billion you mention, you failed to mention the source of that estimate which came from Jay Flatley of Illumina

Exosomes largely underestimated

...
...
Former Illumina CEO Jay Flatley has estimated the total addressable market for a test capable of detecting Stage 2 cancer to be between $20 billion and $40 billion. If a test can detect Stage 1 cancer in addition to the tissue of origin, Flatley said in Jan. 2016 presentation the market could be worth a staggering $100 billion to $200 billion.
...
...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=128932052

Any long shareholder not willing to question WHY this BOD shake up had occurred, may want to review the history of Peregrine Pharmaceuticals and all the facts behind Clinical Supplies Management CEO Gerald Finken and Bristol Myers Squibb competitors to PS Targeting phase II regulatory trial Bavituximab+Docetaxel

Opdivo literally would have been written off if it was not for Jeanette Bleecker and all involved in the sabotage.

I would advise others to seek all sealed documents from all CSM lawsuits that were sealed, including the lawsuit Peregrine filed against CSM in Fargo ND....as well as seeking all sealed documents regarding the class action against Peregrine that the judge threw out not once, twice or three times...but was it the 4th time that Peregrine class action showed no wrong doing ....vs the CSM sabotage trial that the judge said intent/fraud COULD have been charged but was not the way the lawsuit was initiated so we have those sealed records for the jury to see all the facts one day...

Not all info is posted as some may make some not happy

I guess know we can blame Jay Flatley for such estimates : ) and remember Jay has close ties to MSK where Dr Jedd Wolchok has closer ties

https://www.pmwcintl.com/jay-flatley/

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136530297

Jay T. Flatley, 64
Independent Director, Coherent, Inc.
Mr. Jay T. Flatley is Chairman at Helix OpCo LLC and Executive Chairman at Illumina, Inc. He is on the Board of Directors at Juno Therapeutics, Inc., Coherent, Inc., Denali Therapeutics, Inc., GenVault Corp., Helixis, Inc. and Keck Graduate Institute of Applied Life Sciences. Mr. Flatley was previously employed as President & Chief Executive Officer by Bruker AXS, Inc., President, Chief Executive Officer & Director by Molecular Dynamics, Inc., VP-Engineering & Strategic Planning by Plexus Computers LLC, and Chairman by GRAIL, Inc. (California). He received his undergraduate degree from Stanford University, an undergraduate degree from Claremont McKenna College and a graduate degree from Stanford University.

[Protector]

CP did not inflate it, the marked estimation sources have been given.

I never said PPHM would make that much with it, but that there was a huge market, which I think is correct. Well again, I didn't calculate neither launch that number.

And it was based on all the qualifications advertised by UTSW and PPHM:
binary detection, qualification, progression, follow up, no centrifugal work, etc, etc,etc.
That was the condition under which the sources said that the market was about 200 Billion. And there was everything to say for it. Everyone wants a clean quick test and not all the XYZ to go through the current various cancer tracing tests. But did BP want a quick cheap test if they make those billions today?

And, FYI, that so called 'screw-up' was also taken over by Oncologie.

Wanted to answer this one for some time.

Then again, supporting your statement to be complete, I don't find that IP anywhere in the transfer list although exosomes are mentioned. And the product was ready for launch (it was even in the cost justification at the time).

So i will agree with you that something fishy happened, I will not agree that the program was a screw up (from a technical-medical point of view rather then a transfer one).

PS: When I had access again, it was to late to react to your request.